<DOC>
	<DOCNO>NCT01121211</DOCNO>
	<brief_summary>The investigator investigate whether hormone naturally produce human body , call testosterone , help improve weight , disorder eating , depression , anxiety . The investigator hypothesize testosterone novel effective endocrine-targeted therapy patient anorexia nervosa .</brief_summary>
	<brief_title>Hormonal Factors Treatment Anorexia Nervosa</brief_title>
	<detailed_description />
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Age 18 45 year ; participate neuroimaging sub study , age 1840 Meet DSMIV criterion AN ( restrict binge/purge type , BMI 1517.5 ) OR meet criterion subthreshold AN , i.e. , DSMIV criterion except patient BMI &lt; 18.5 kg/m2 without amenorrhea . Free T median healthy woman reproductive age All participant require treatment team place consist ( least ) primary care physician psychotherapist . Participants need regular contact primary care physician individual psychotherapy program . Participants agree continue treatment team therapy throughout active course study . If participant take psychotropic medication , dose must stable 3 month study entry Pregnant woman woman child bear potential use medically accept mean contraception ( include oral contraceptive , patch implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) . Unstable medical illness , include cardiovascular , hepatic , renal , respiratory , endocrine , neurologic Serious suicide risk , substance use disorder active within last 6 month , bipolar I disorder , severe current depressive symptom ( indexed HAMD score &gt; 20 [ exclude 2 eating/weight loss item relate symptom AN ] ) , psychotic disorder New psychotropic drug regimen , specifically significant dose change change drug class , within last 6 week . A study psychiatrist ass whether PRN medication dose change clinically significant enough defer enrollment specific potential study subject . Untreated hypothyroidism If receive estrogen therapy , include oral contraceptive transdermal estrogen therapy , significant change dose prior 3 month Use androgens androgen precursor , include T , DHEA methyl T , within 3 month Any investigational psychotropic drug within last 3 month In judgment study clinician , unlikely able participate safely throughout study period Alanine aminotransferase ( ALT ) &gt; 2x upper limit normal Creatinine &gt; 1.5x upper limit Serum potassium &lt; low limit normal If participate sub study , unable tolerate 1 hour MRI ; contraindication MRI ( implant pacemaker , cerebral aneurysm clip , extensive orthopedic hardware instrumentation ) ; gastrointestinal tract surgery ( include gastrectomy , gastric bypass surgery , small large bowel resection ) ; history psychosis SCID</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Hormones</keyword>
	<keyword>Mental Health</keyword>
</DOC>